Fill in your contactinformation to download the whitepaper

Whitepaper consent
Newsletter consent

HERAN Investor Day 2026: Fueling bold innovators for the long run

November 18, 2026 - Waasmunster (BE)

Once a year, we invite our investors, founders and partners to take a look behind the scenes. On October 21st , over 100 guests joined us at De Koolputten in Waasmunster for an honest look at the past twelve months. An evening about the establishment of a new fund (HERAN HealthTech Fund II) , innovative technologies and the people behind them. 

Katleen Vandersmissen (Managing Partner) and Raf Roelands (Partner) opened the evening with an overview of HERAN’s past year, and a glimpse of the years ahead. 

Katleen

 

Fund II: established

By Investor Day, HERAN HealthTech Fund II had reached €108m in commitments. HERAN HealthTech Fund II held its second closing in March at €91m. By October 21st , commitments had reached €108m, and the day after the event the fund made its third investment (Incision). 

We assessed many companies, and the deal flow pipeline was full. Even so, we never rushed. The first investments were chosen carefully, because they set the tone for those to follow. 

 

Fund I: Value creation is not a straight line

For Fund I, we’re in the harvest period now – the work is no longer about selecting companies and getting them started, but about growing them. These are maturing businesses, each scaling in their own way. Sometimes, that means commercial growth; sometimes it’s building evidence for clinical relevance. 

Value creation takes a different form every time. A company might go through a period difficult enough that we question whether to continue. Then it turns a corner and grows again. 

 

AI: it’s about people

AI was once again on the agenda, this time with a clear reminder. Many promising companies, including several in our portfolio, are using AI technology to make healthcare safer, faster or more precise. Healthcare is not an accounting system – it’s about more than data and numbers. AI can solve a great deal, but there will always be a human ‘in the loop’, an expert who works with it. 

That goes for how we invest, too. We invest in bold innovators and ambitious teams who combine promising technologies with the determination to bring them to life. Turning innovation into real-world impact takes more than a great idea. 

From the portfolio

In the second part of the evening, founders from Fund I and Fund II  presented their companies.

Eva van Rikxoort, founder and  CEO of Thirona (NL), made the case for lung disease. Alongside cancer and cardiovascular disease, it’s one of the largest health challenges we face. Thirona develops AI-powered software that provides high-precision medical image analysis, specifically chest CT scans and X-rays.

Enric Gibert, Founder of Pharmacelera (ES), explained how the company combines quantum mechanics algorithms with artificial intelligence to develop software that speeds up the design–make–test–analyse (DMTA) cycle at the heart of drug discovery.

Bringing it closer to home, Stijn Verhulst, Head of Paediatrics at Antwerp University Hospital, spoke about Project Oever, an initiative that HERAN supports. It connects hospital, family, and primary care so that children with severe illness can receive the care they need at home.  Although our roles are different, both HERAN and Project Oever share a common purpose: enabling better healthcare by connecting the right expertise, people and resources.

The evening ended with a walking dinner and engaging conversations. 
The companies we invest in have moved forward, but our story remains the same. Building a company in this sector is not a sprint; it’s a marathon. We intend to run it alongside our founders.

Thank you to everyone who joined us. We look forward to seeing you next year. 

Overview Serre

 

Scene Food

 

Studiovision heran 261021 investorday LR 083 SV9 8878

 

Studiovision heran 261021 investorday LR 088 SV9 8911

 

Studiovision heran 261021 investorday LR 119 SV9 9183

 

Studiovision heran 261021 investorday LR 123 SV9 9203

 

Studiovision heran 261021 investorday LR 138 SV9 9371

 

Studiovision heran 261021 investorday LR 139 SV9 9376

 

Studiovision heran 261021 investorday LR 151 SV9 9504

 

Studiovision heran 261021 investorday LR 154 SV9 9542

 

Studiovision heran 261021 investorday LR 157 SV9 9593

 

Studiovision heran 261021 investorday LR 171 SV9 9770

 

Studiovision heran 261021 investorday LR 180 SV9 9830

 

Studiovision heran 261021 investorday LR 181 SV9 9843